SK284029B6 - Farmaceutická kompozícia na liečenie roztrúsenej sklerózy - Google Patents
Farmaceutická kompozícia na liečenie roztrúsenej sklerózy Download PDFInfo
- Publication number
- SK284029B6 SK284029B6 SK931-99A SK93199A SK284029B6 SK 284029 B6 SK284029 B6 SK 284029B6 SK 93199 A SK93199 A SK 93199A SK 284029 B6 SK284029 B6 SK 284029B6
- Authority
- SK
- Slovakia
- Prior art keywords
- copolymer
- cells
- eae
- day
- fed
- Prior art date
Links
- GDOPTJXRTPNYNR-UHFFFAOYSA-N CC1CCCC1 Chemical compound CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
- Peptides Or Proteins (AREA)
- General Preparation And Processing Of Foods (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL11998997A IL119989A0 (en) | 1997-01-10 | 1997-01-10 | Pharmaceutical compositions for oral treatment of multiple sclerosis |
PCT/US1998/000375 WO1998030227A1 (en) | 1997-01-10 | 1998-01-12 | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
Publications (2)
Publication Number | Publication Date |
---|---|
SK93199A3 SK93199A3 (en) | 2000-11-07 |
SK284029B6 true SK284029B6 (sk) | 2004-08-03 |
Family
ID=11069682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK931-99A SK284029B6 (sk) | 1997-01-10 | 1998-01-12 | Farmaceutická kompozícia na liečenie roztrúsenej sklerózy |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0975351B1 (ko) |
JP (1) | JP4216342B2 (ko) |
KR (1) | KR20000070058A (ko) |
CN (1) | CN100528222C (ko) |
AT (1) | ATE356608T1 (ko) |
AU (1) | AU737287B2 (ko) |
BR (1) | BRPI9807076B8 (ko) |
CA (1) | CA2277365C (ko) |
CZ (1) | CZ297983B6 (ko) |
DE (1) | DE69837324T2 (ko) |
EA (1) | EA003128B1 (ko) |
HK (1) | HK1025737A1 (ko) |
HU (1) | HU226612B1 (ko) |
IL (2) | IL119989A0 (ko) |
NZ (1) | NZ336690A (ko) |
PL (1) | PL193300B1 (ko) |
SK (1) | SK284029B6 (ko) |
WO (1) | WO1998030227A1 (ko) |
ZA (1) | ZA98214B (ko) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2337688C (en) | 1998-07-23 | 2016-04-05 | Yeda Research And Development Co., Ltd. | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
WO2000005249A2 (en) * | 1998-07-23 | 2000-02-03 | The President And Fellows Of Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
EP1187612B1 (en) * | 1999-06-04 | 2005-01-26 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Use of riluzole for the treatment of multiple sclerosis |
DE60041365D1 (de) * | 1999-06-04 | 2009-02-26 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Verwendung von Riluzol zur Behandlung Multipler Sklerose |
DE60120648D1 (de) * | 2000-02-18 | 2006-07-27 | Yeda Res & Dev | Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung |
ZA200206457B (en) | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
HUP0302333A3 (en) * | 2000-06-05 | 2005-07-28 | Teva Pharma | The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders |
WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
WO2003048735A2 (en) | 2001-12-04 | 2003-06-12 | Teva Pharmaceutical Industries, Ltd. | Processes for the measurement of the potency of glatiramer acetate |
SI2336184T1 (sl) | 2002-02-25 | 2015-04-30 | Biogen Idec Ma Inc. | Dajanje sredstev za zdravljenje vnetij |
CA2514125A1 (en) * | 2003-01-24 | 2004-08-12 | Elan Pharmaceuticals, Inc. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
US7560100B2 (en) | 2004-09-09 | 2009-07-14 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases |
CZ30474U1 (cs) | 2009-08-20 | 2017-03-14 | Yeda Research And Development Co., Ltd. | Glatiramer acetát a terapeutická kompozice s jeho obsahem pro použití k léčení s nízkou frekvencí ošetření |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
NZ609938A (en) | 2010-10-11 | 2015-11-27 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
US8815511B2 (en) | 2011-10-10 | 2014-08-26 | Teva Pharmaceutical Industries, Ltd. | Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate |
TW201420111A (zh) | 2012-10-10 | 2014-06-01 | Teva Pharma | 對格拉默醋酸鹽(glatiramer acetate)之臨床反應具預測性之生物標記 |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
CN105884866B (zh) * | 2015-01-26 | 2021-04-20 | 漳州未名博欣生物医药有限公司 | 格拉替雷的化学合成方法 |
US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
US10330650B2 (en) * | 2015-04-28 | 2019-06-25 | Hybio Pharmaceutical Co., Ltd. | High performance liquid chromatography method for polypeptide mixtures |
EP3600553A4 (en) | 2017-03-26 | 2020-09-02 | Mapi Pharma Ltd. | GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS |
EP3645029B1 (en) | 2017-06-26 | 2023-01-18 | Institut Pasteur | Treatments to eliminate hiv reservoirs and reduce viral load |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
US5719296A (en) * | 1995-10-30 | 1998-02-17 | Merck & Co., Inc. | Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins |
-
1997
- 1997-01-10 IL IL11998997A patent/IL119989A0/xx unknown
-
1998
- 1998-01-12 PL PL334566A patent/PL193300B1/pl unknown
- 1998-01-12 SK SK931-99A patent/SK284029B6/sk not_active IP Right Cessation
- 1998-01-12 CA CA2277365A patent/CA2277365C/en not_active Expired - Lifetime
- 1998-01-12 EA EA199900621A patent/EA003128B1/ru not_active IP Right Cessation
- 1998-01-12 BR BRPI9807076A patent/BRPI9807076B8/pt not_active IP Right Cessation
- 1998-01-12 ZA ZA9800214A patent/ZA98214B/xx unknown
- 1998-01-12 CZ CZ0243799A patent/CZ297983B6/cs not_active IP Right Cessation
- 1998-01-12 KR KR1019997006278A patent/KR20000070058A/ko active Search and Examination
- 1998-01-12 AU AU58195/98A patent/AU737287B2/en not_active Expired
- 1998-01-12 AT AT98901745T patent/ATE356608T1/de not_active IP Right Cessation
- 1998-01-12 NZ NZ336690A patent/NZ336690A/en not_active IP Right Cessation
- 1998-01-12 JP JP53110898A patent/JP4216342B2/ja not_active Expired - Lifetime
- 1998-01-12 HU HU0001917A patent/HU226612B1/hu unknown
- 1998-01-12 CN CNB988031221A patent/CN100528222C/zh not_active Expired - Lifetime
- 1998-01-12 DE DE69837324T patent/DE69837324T2/de not_active Expired - Lifetime
- 1998-01-12 WO PCT/US1998/000375 patent/WO1998030227A1/en active IP Right Grant
- 1998-01-12 EP EP98901745A patent/EP0975351B1/en not_active Expired - Lifetime
-
1999
- 1999-07-06 IL IL130820A patent/IL130820A/en not_active IP Right Cessation
-
2000
- 2000-08-01 HK HK00104810A patent/HK1025737A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE356608T1 (de) | 2007-04-15 |
HK1025737A1 (en) | 2000-11-24 |
JP2001511121A (ja) | 2001-08-07 |
AU5819598A (en) | 1998-08-03 |
WO1998030227A1 (en) | 1998-07-16 |
NZ336690A (en) | 2001-05-25 |
CN1249690A (zh) | 2000-04-05 |
EP0975351A1 (en) | 2000-02-02 |
EA003128B1 (ru) | 2003-02-27 |
CN100528222C (zh) | 2009-08-19 |
PL193300B1 (pl) | 2007-01-31 |
EP0975351A4 (en) | 2002-05-15 |
CA2277365C (en) | 2011-04-12 |
EP0975351B1 (en) | 2007-03-14 |
IL119989A0 (en) | 1997-04-15 |
KR20000070058A (ko) | 2000-11-25 |
CA2277365A1 (en) | 1998-07-16 |
BRPI9807076B8 (pt) | 2021-05-25 |
ZA98214B (en) | 1999-08-11 |
AU737287B2 (en) | 2001-08-16 |
HUP0001917A3 (en) | 2001-12-28 |
DE69837324T2 (de) | 2007-11-29 |
HUP0001917A2 (hu) | 2000-10-28 |
BR9807076B1 (pt) | 2013-10-29 |
PL334566A1 (en) | 2000-03-13 |
EA199900621A1 (ru) | 2000-02-28 |
IL130820A (en) | 2007-03-08 |
BR9807076A (pt) | 2000-05-02 |
CZ297983B6 (cs) | 2007-05-16 |
JP4216342B2 (ja) | 2009-01-28 |
DE69837324D1 (de) | 2007-04-26 |
HU226612B1 (en) | 2009-04-28 |
CZ243799A3 (cs) | 2000-06-14 |
SK93199A3 (en) | 2000-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK284029B6 (sk) | Farmaceutická kompozícia na liečenie roztrúsenej sklerózy | |
US6214791B1 (en) | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 | |
WO1998030227A9 (en) | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 | |
JP3712260B2 (ja) | 自己免疫疾患のバイスタンダー抑制 | |
AU742970B2 (en) | Method of suppressing beta-amyloid-related changes in Alzheimer's disease | |
CN106668852B (zh) | 一种治疗和/或预防ⅰ型糖尿病的组合物及其应用 | |
JP2527749B2 (ja) | 移植拒否反応抑制または自己免疫疾患治療用薬学的組成物 | |
EP2523668A1 (en) | Treatment of multiple sclerosis | |
EP2046366B1 (en) | Copolymer-1 for treatment of age-related macular degeneration | |
AU2003250892A1 (en) | Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors | |
RU2647438C2 (ru) | Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей | |
HUT74900A (en) | Treatment of autoimmune disease using oral tolerization and/or type i interferon | |
Hayashi et al. | Protective role of nitric oxide in ocular toxoplasmosis. | |
KR100435040B1 (ko) | 티세포매개성질환들의치료를위한제제들및방법들 | |
Sela | Immunomodulatory vaccines against autoimmune diseases | |
US8349314B2 (en) | Method of treating and/or preventing type II diabetes using Actinomycetales | |
EP4353234A1 (en) | Use of pyrrolopyrimidine compound | |
MXPA99006457A (en) | Treatment of multiple sclerosisthrough ingestion or inhalation of copolymer-1 | |
US20240238299A1 (en) | Use of pyrrolopyrimidine compound | |
WO2023037160A2 (ru) | Набор и разовая дозированная форма для профилактики сахарного диабета 1 типа, их применение для профилактики сахарного диабета 1 типа. способ профилактики сахарного диабета 1 типа у здоровых людей из группы высокого риска |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4A | Patent expired |
Expiry date: 20180112 |